BlossomHill Therapeutics, Inc. BLSM
11.81 USD -0.60 (-4.84%)
Nov 4, 2026, 2:44 PM EST
11.24 Day range 13.00
11.24 52-week range 27.99
- YTD
- -26.19%
- 1 year
- -26.19%
- Market cap
- 375.70M
- EPS (ttm)
- -4.70
- YTD return
- -26.19%
- 1-year return
- -26.19%
- Volume
- 205.97K
- Avg volume
- 224.27K
- Open
- 12.45
- Previous close
- 12.41
- Day's range
- 11.24 – 13.00
- 52-week range
- 11.24 – 27.99
YTD -4.16 (-26.00%)
Financials — quick view
BLSM Revenue — quarterly 0
BLSM Net income — quarterly -23.76M
BLSM EPS — quarterly -8.75
News
BlossomHill Therapeutics Announces Upcoming Presentation for BH-30236, an Oral Macrocyclic CLK Inhibitor, at the 68th American Society of Hematology (ASH) Annual Meeting 
BlossomHill Therapeutics to Present at Guggenheim's 3rd Annual Healthcare Innovations Conference 
BlossomHill Therapeutics: A Deliberate Beachhead Trading Back At Its IPO Price 
BlossomHill Therapeutics Collaborates With Foundation Medicine To Develop Companion Diagnostic Assay For EGFR C797S Resistance Mutation 
BlossomHill Therapeutics Announces Collaboration with Foundation Medicine to Develop First Companion Diagnostic for BH-30643 in EGFR C797S Mutated Non-Small Cell Lung Cancer 
BlossomHill Therapeutics (NASDAQ:BLSM) Shares Down 4.9% – Time to Sell? 
BlossomHill Therapeutics (NASDAQ:BLSM) Shares Gap Up – Here’s Why 
BlossomHill Therapeutics Presents Preclinical Data On BH-501284 At AACR Conference On Pancreatic Cancer; Targets IND Filing In Q1 2027 
BlossomHill Therapeutics Presents Preclinical Data on Novel Pan-KRAS Inhibitor, BH-501284, at the AACR Conference on Pancreatic Cancer 
Leerink Partners Maintains Outperform on BlossomHill Therapeutics, Raises Price Target to $40
Your note
Sign in to keep a note on BLSM — it syncs with the Stock Master app.